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Background: PDPN is a transmembrane receptor that
promotes cell migration, but modifications that regulate
its effects are not known.
Results: PKA can phosphorylate PDPN, nonphosphory-
latable PDPN promotes cell migration, and phosphomi-
metic PDPN fails to promote cell migration.
Conclusion: PKA can phosphorylate PDPN to decrease
cell migration.
Significance: PDPN effects on cell motility are important
for processes including embryonic development and can-
cer progression.
Podoplanin (PDPN) is a transmembrane receptor that affects
the activities of Rho, ezrin, and other proteins to promote tumor
cell motility, invasion, and metastasis. PDPN is found in many
types of cancer and may serve as a tumor biomarker and chemo-
therapeutic target. The intracellular region of PDPNcontains only
two serines, and these are conserved in mammals including mice
andhumans.Wegenerated cells from the embryos of homozygous
nullPdpn knock-outmice to investigate the relevance of these ser-
ines to cell growth and migration on a clear (PDPN-free) back-
ground. We report here that one or both of these serines can be
phosphorylated by PKA (protein kinase A). We also report that
conversion of these serines to nonphosphorylatable alanine residues
enhances cell migration, whereas their conversion to phosphomi-
metic aspartate residues decreases cell migration. These results indi-
cate thatPKAcanphosphorylatePDPNtodecreasecellmigration. In
addition,we report that PDPNexpression in fibroblasts causes them
to facilitate the motility and viability of neighboring melanoma
cells in coculture. These findings shed new light on how PDPN
promotes cell motility, its role in tumorigenesis, and its utility as a
functionally relevant biomarker and chemotherapeutic target.
PDPN2 (also called OTS8, RTI40, T1, aggrus, and gp36) is a
transmembrane mucin-like protein that augments tumor cell
invasion. PDPN is required for proper lung and lymphatic sys-
tem development during embryogenesis (1–3). However,
PDPN expression is also induced by tumor promoters includ-
ing 12-O-tetradecanoylphorbol-13-acetate, RAS, and Src
(4–6) and is found at the invasive front of many types of cancer
(7, 8). Indeed, PDPNmay serve as a cancer biomarker and effec-
tive chemotherapeutic target (8–10).
PDPN regulates the activities of Rho, ezrin, and other pro-
teins linked to the actin cytoskeleton to mediate filopodia for-
mation, cell motility, invasion, and metastasis (8, 11). Some
proteins that control the actin cytoskeleton can be modified by
phosphorylation to affect cell motility. For example, the adap-
tor proteins Cas, paxillin, and palladin affect remodeling of the
actin cytoskeleton and are phosphorylated as a result of onco-
genic kinase signaling cascades to promote or inhibit tumor cell
motility (12–15).
PDPN is a unique transmembrane receptor protein that con-
sists of an N-terminal extracellular domain of about 140 amino
acids, a transmembrane domain of about 20 amino acids, and a
short intracellular C-terminal domain of about 10 amino acids.
The intracellular tail of PDPN contains two serine residues that
are conserved in all mammals. However, the function of these
two intracellular serines has not been elucidated. Here, we
report that these serine residues influence the effects of PDPN
on cell motility and intercellular interactions between fibro-
blasts and tumor cells.
EXPERIMENTAL PROCEDURES
Kinase Assays—Phosphorylation of the peptide VVMKKIS-
GRFSP (synthesized by Proteintech, Chicago, IL), containing
the entire intracellular region of mouse PDPN (residues 161–
172), was measured using a phosphocellulose paper binding
assay (16). Reaction mixtures contained 300 M peptide in 20
mM Tris-HCl (pH 7.4), 10 mM MgCl2, 1 mg/ml bovine serum
albumin, 0.25 mM ATP, and [-32P]ATP (100 cpm/pmol). The
reactions were initiated by the addition of 25 g/ml PKA (Pro-
megaV516A).Aliquotswerewithdrawnatvarious timepointsand
quenched by the addition of 10% trichloroacetic acid. The reac-
tionswere spottedontoP81phosphocellulose filters,washed three
times with 0.5% phosphoric acid, and analyzed by scintillation
counting to determine the picomoles of phosphate transferred.
Generation of Wild Type and Mutant Pdpn Cell Lines—
PdpnKo3 cells were isolated from the trunks of homozygous
null Pdpn knock-out mice at day 10 postcoitum (1). Cells were
maintained in DMEM supplemented with 10% FBS as
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described previously (15, 17). The cells passed crisis during
standard serial passaging, and genotypes were verified by PCR.
Pdpn mutant constructs were produced with the QuikChange
II XL site-directed mutagenesis kit according to the manufac-
turer’s protocol (Stratagene 200521). The vector pEF4Pdpn
encoding full-length wild type mouse PDPN (PdpnWT) (4, 18)
was used as a template. Pdpn(S167A/S171A) encoding non-
phosphorylatable PDPN (PdpnAA) was generated with the
complementary primer pairs 5-GTTGTTATGAAGAAGAT-
TGCTGGAAGGTTCTCGCC-3, 5-GGCGAGAACCTTC-
CAGCAATCTTCTTCATAACAAC-3 followed by 5-TGG-
AAGGTTCGCGCCCTAAAGAGGGCCCTTCGAAGG-3,
5-CCTTCGAAGGGCCCTCTTTAGGGCGCGAACCTT-
CCA-3. Pdpn(S167D/S171D) encoding phosphomimetic







structs were verified by sequencing. PdpnWT, PdpnAA,
PdpnDD constructs, and the control vector pEF4/V5HisA (In-
vitrogen) were cotransfected with pBABEpuro into a single ex-
panded PdpnKo cell clone with Lipofectamine 2000 according
to the manufacturer’s protocol (Invitrogen 11668-027). Trans-
fectants were selected with Zeocin (InvivoGen ant-zn-1p) and
puromycin (Calbiochem 540411). This double transfection/
selection technique produces high levels of transgene expres-
sion in about 80% or more of surviving cells (4, 15, 19).
Western Blotting—Western blotting was performed as
described previously (4, 18). Protein was resolved by SDS-
PAGE, transferred to Immobilon-P membranes (Millipore
IH1079562), and incubated with antisera specific for PDPN
(University of Iowa Developmental Studies Hybridoma Bank
8.1.1), or GAPDH (Santa Cruz Biotechnology A1978). Primary
antiserum was recognized by appropriate secondary antiserum
conjugated to horseradish peroxidase and detected using
enhanced chemiluminescence (Thermo Scientific 32106).
After blotting, membranes were stained with India ink to verify
equal loading and transfer.
Evaluation of Cell Growth and Migration—Cell growth and
migrationwere evaluated as described previously (4, 15, 18, 19).
Briefly, cell growth was measured by plating 10,000 cells/well
on standard 24-well tissue culture plates (Falcon 353047) and
counting cells at the indicated time points in a Coulter counter.
For wound healing migration assays, confluent cell monolayers
were scratched, and migration was quantitated as the number
of cells that entered a 300  200-m area in the center of the
wound at 18 h. For some experiments, the PKA modulators
8-Br-cAMP (Calbiochem 203800) or H-89 (Calbiochem
371963) were added immediately after wounding. For Tran-
swell invasion assays, 600,000 cells were added to each chamber
of 6-well Transwell membranes with an 8-m pore size (Tran-
swell-Clear, Costar 3428), incubated for 24 h, released sepa-
rately from the top and bottom of the membrane, counted in a
Coulter Counter, and quantified as the percentage of cells that
migrated from the top of the membrane to the bottom of the
membrane.
Video Microscopy—To analyze unopposed movement,
PdpnKo cell lines were plated on 35-mm culture dishes at 5%
confluence and incubated overnight. To analyze the effects of
PdpnKo cells on themovement of melanoma cells in coculture,
B16F10 melanoma cells were labeled with 1,1-dioctadecyl-
3,3,33-tetramethylindocarbocyanine perchlorate as described
(17, 20, 21), plated with unlabeled B16F10 cells or PdpnKo cell
lines at a 1:100 ratio on 35-mm culture dishes at 85% conflu-
ence, and incubated overnight. Mediumwas then removed and
replaced with fresh medium before dishes were mounted on an
INUBG2A-ZILCS with UNIV-35 stage top incubator (Tokai
Hit, Shizuoka, Japan) maintained at 37 °C, 5% CO2, and 100%
humidity. Images of cells were captured with AxioCam MRm
camera at 5-min intervals for 18 (unopposed movement) or
36 h (cocultured melanoma cells) with a 5 CP-Achromat
objective on a Zeiss Axiovert 40 CFL inverted microscope or a
10 EC Plan NEOF objective with a Zeiss Axiovert Observer
Z1 inverted microscope, respectively. Distance and displace-
ment traveled from the starting point to the end point were
measured by tracking the center of the nuclei of motile cells
withAxioVision software (version 4.3, Carl Zeiss). The percent-
age of morphologically intact cells was used to quantitate the
survival of cocultured melanoma cells.
Statistical Analysis—Experiments were repeated with simi-
lar results and means, errors, and unpaired two-tailed t tests
were calculated from representative data sets with Prism (ver-
sion 4, GraphPad Software).
RESULTS
Phosphorylation of thePDPNIntracellularTail byPKA—PDPN
activity correlates well between humans and mice (22). For
example, PDPN expression is strongly induced in human (22,
23) and mouse (5, 24) skin cancers. There are 2 conserved ser-
ines in the intracellular region of mouse and human PDPN.
These serine residues could potentially serve as phosphoryla-
tion sites for PKC or PKA. Using a peptide that corresponds to
the entire cytoplasmic portion of PDPN, we performed in vitro
kinaseassays toevaluate theabilityof thesekinases tophosphor-
ylate these sites. As shown in Fig. 1, PKA catalyzed the time-de-
pendent phosphorylation of the PDPN cytoplasmic peptide. In
contrast, PKC did not phosphorylate the peptide to any signif-
icant extent (data not shown).
Nonphosphorylated PDPN Enhances Cell Migration—We
generated homozygous null Pdpn knock-out mouse embryonic
fibroblasts (PdpnKo cells) to study the effects of PDPNmodifi-
cation on cell behavior. The absence of endogenous PDPN
background of these cells facilitated evaluation of how modifi-
cation of PDPN intracellular serines affected cell growth and
motility. These cells were stably transfected with constructs
encoding wild type PDPN (PdpnWT), nonphosphorylatable
PDPN with both intracellular serines mutated to alanine
(PdpnAA), phosphomimetic PDPN with both intracellular serines
mutated to aspartate (PdpnDD), or empty vectors (PdpnEF4) as
controls. Expression of these transgenes was verified by Western
blotting as shown in Fig. 2a.
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Although PDPN has been shown to promote cell migration,
its effects on cell growth and proliferation are less defined
(8–10). A role for PDPN in cell growth seemed to emerge on the
clear background of homozygous null knock-out cells. As
shown in Fig. 2b, expression of wild type (PdpnWT) or non-
phosphorylatable (PdpnAA) PDPN appeared to decrease cell
growth rates by about 50% when compared with control trans-
fectants (PdpnEF4). Interestingly, this effect was not seen in
cells transfected with the phosphomimetic PDPN (PdpnDD)
construct.
As expected, wild type PDPN augmented the migration of
PdpnKo cells. PdpnWTcellsmigrated about 50%more than the
control transfectants (PdpnEF4) in wound healing migration
assays shown in Fig. 2, c and d. However, although expression of
the PdpnAA construct did not exceed that of PdpnWT, PdpnAA
cells migrated about 40% more than PdpnWT cells in these
assays. These results were confirmed by Transwell invasion
assays in which PdpnWT cells moved about 4-fold better
through 8-m pores than PdpnEF4 cells, and PdpnAA cells
moved about 50% more than the PdpnWT cells (Fig. 2e).
Phosphomimetic PDPN Decreases Cell Migration—Results
fromwild type (PdpnWT) and nonphosphorylatable (PdpnAA)
constructs suggest that PDPN can be phosphorylated to
inhibit cell migration. This hypothesis is supported by results
from phosphomimetic (PdpnDD) constructs. In contrast to
PdpnWT or PdpnAA constructs, phosphomimetic (PdpnDD)
Pdpndid not significantly increase cellmotilitywhen compared
with PdpnEF4 control cells in wound healing migration (Fig. 2,
c and d) or Transwell invasion (Fig. 2e) assays. Interestingly, in
contrast to wild type or PdpnAA transfectants, PdpnDD trans-
fection did not significantly decrease cell growth when com-
pared with PdpnEF4 controls (Fig. 2b). These results suggest
that PDPN signaling may convert some metabolic energy used
for cell proliferation into processes needed for motility.
Live Cell Imaging of Individual Cells Confirms That PDPN
Serine Residue Modifications Affect Cell Motility—PDPN can
promote both collective and individual cell migration in the
absence or presence of epithelial-mesenchymal transition (7,
25). Thus, in addition to wound healing and Transwell assays,
live cell imaging was used to investigate the effects of PDPN
serinemodifications on themotility of individual cells in sparse
cultures. These assays also allowed direct measurements of
total displacement and distance traveled by individual cells over
time.
As with wound healing and Transwell assays cells, PDPN
transfectants moved better than control cells, and nonphos-
phorylatable PDPN increased the motility of these cells more
than wild type PDPN. PdpnKo cells transfected with PdpnEF4,
PdpnWT, or PdpnAAmoved at an average displacement speed
of 1.6, 3.7, or 4.2 m/h (Fig. 2f and supplemental Fig. 1, a-c) to
travel an average distance of 3.4, 6.2, or 11 m/h, respectively.
In contrast, the movement of cells transfected with phospho-
mimetic PDPN (PdpnDD) was not significantly different from
controls (PdpnEF4) when measured by displacement (1.3
m/h) and significantly less than controls when measured by
distance (1.9 m/h) (Fig. 2f and supplemental Fig. 1d). These
data indicate that PDPN can be phosphorylated to decrease
both collective and individual cell motility.
Modulators of PKAActivity AffectMigration of Cells Express-
ing Wild Type PDPN—Results from kinase assays and site
mutants suggest that PKA activation inhibits PDPN-mediated
cell migration. As shown in Fig. 3 and supplemental Fig. 2, the
PKA agonist 8-Br-cAMP significantly decreased the migration
of cells transfectedwithwild type PDPN.Conversely, treatment
of these cells with the PKA blocker H-89 significantly increased
their migration. These data are consistent with the hypothesis
that PKA phosphorylates PDPN to decrease cell migration.
PDPN Expression in Fibroblasts Facilitates Neighboring
Tumor Cell Migration and Survival—PDPN expression in can-
cer-associated fibroblasts has been linked to increased tumor
invasive and metastatic potential (26, 27). We utilized PdpnKo
cells to investigate mechanisms that may underlie the relation-
ship between cancer cells and their neighboring fibroblasts.
Melanoma cells that express PDPN as a functionally relevant
biomarker and potential chemotherapeutic target were chosen
as subjects for this investigation (18).
Melanoma cells migrated an average distance of about 9.2
m/h when surrounded by other melanoma cells (Fig. 4, a and
b, and supplemental Fig. 3a). The migration of melanoma cells
when surrounded by fibroblasts expressing (PdpnWT cells)
was not significantly different from their migration when sur-
rounded by melanoma cells (Fig. 4, a and b, and supplemental
Fig. 3b). However, melanoma cell migration was decreased by
over 50%, to an average distance of only 4.2 m/h, when
surrounded by PdpnEF4 control cells (Fig. 4, a and b). Thus,
fibroblasts expressing PDPN appeared to facilitate the
migration of neighboring tumor cells better than PDPN-de-
ficient fibroblasts.
In addition to increasing tumor cell motility, PDPN expres-
sion in fibroblasts affected the viability of neighboring mela-
noma cells. As shown in Fig. 4, a and c, about 70% of melanoma
cells cocultured with cells lacking Pdpn (PdpnEF4) went
through morphological changes indicative of apoptosis (see
supplemental Fig. 3c) when compared with about 20% of mel-
anoma cells cocultured with PdpnWT cells or 10% cocultured
with other melanoma cells. Also, as shown in Fig. 4, melanoma
cells cocultured with fibroblasts expressing phosphomimetic
PDPN behaved similarly to those cultured with control trans-
FIGURE 1. Phosphorylation of PDPN intracellular tail by PKA. Peptide con-
taining the entire intracellular region of PDPN (VVMKKISGRFSP) was incu-
bated with PKA and [-32P]ATP for the indicated time points. Data are shown
as the picomoles of phosphate transferred to the PDPN peptide (mean  S.D.,
n  2).
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fectants (see supplemental Fig. 3d). Taken together, these data
indicate that PDPN expression levels and phosphorylation sta-
tus in fibroblasts can affect the motility and viability of neigh-
boring tumor cells.
DISCUSSION
PDPN expression enhances the motility and invasion of sev-
eral transformed cell types including mammary carcinoma (7,
8), glioma (28), and squamous carcinoma cells (29–31). PDPN
FIGURE 2. Effect of Pdpn expression on cell growth and motility. a, PDPN and GAPDH were detected by Western blotting of protein (7.5 g/lane) from
homozygous null Pdpn knock-out mouse embryonic fibroblasts transfected with empty parental vector (EF4), wild type Pdpn (WT), Pdpn with both intracellular
serines mutated to alanine (AA), or Pdpn with both intracellular serines mutated to aspartate (DD) as indicated. b, cell growth was evaluated by plating 10,000
cells/well on 24-well tissue culture plates and counting at the indicated time points. Data are shown as number of cells/well (mean  S.D., n  2). c and d, cell
migration was measured by wound healing assays and quantitated as the number of cells that entered a 300  200-m area of in the center of a wound in 18 h
(mean  S.E., n  12). Bar  100 m. e, Transwell invasion assays were performed and quantitated as the percentage of cells that moved from the top of the
membrane to the bottom of the membrane in 24 h (mean  S.E., n  3). f and g, total displacement (f) and net distance (g) traveled were measured by video
microscopy of individual motile cells and presented as micrometers traveled over 18 h (mean  S.E., n  20). Single, double, and triple asterisks indicate p  0.05,
p  0.01, and p  0.001 when compared with empty vector controls by Student’s t test, respectively.
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is found at the invasive front of many tumors, which is consist-
ent with its role in promoting invasion (7, 8). In addition to
tumor cells themselves, PDPN is also located on endothelial
cells of lymphatic vessels, which can facilitate tumor invasion
and metastasis (32, 33). PDPN expression in cancer-associated
fibroblasts has also been linked to tumor aggression and poor
prognosis of lung cancers (26, 27, 34, 35). Consistent with these
findings, our results indicate that PDPN expression in fibro-
blasts can facilitate migration and survival of neighboring
tumor cells in the microenvironment. Further elucidation of
events underlying this relationship should lead to a greater
understanding of fundamental mechanisms that guide stroma-
tumor interactions and how they may be exploited to combat
cancer.
Indeed, PDPN presents great potential as a functionally rel-
evant biomarker and chemotherapeutic target (8–10). For
example, reagents that target PDPN and a PDPN-interacting
partner (tetraspanin CD9) can inhibit lung metastasis of CHO
FIGURE 3. Effect of PKA modulators on cell migration. Wound healing experiments were performed on confluent monolayers of PdpnWT cells treated with
the PKA agonist 8-Br-cAMP or PKA inhibitor H-89 as indicated. Cell migration was quantitated as the number of cells that entered a 300  200-m area of in the
center of a wound in 18 h (mean  S.E., n  6). Single and triple asterisks indicate p  0.05 and p  0.001 when compared with untreated controls by Student’s
t test.
FIGURE 4. Effect of Pdpn expression on the motility of neighboring melanoma cells. a, movement of 1,1-dioctadecyl-3,3,33-tetramethylindocarbocya-
nine perchlorate-labeled B16 melanoma cells cocultured with unlabeled B16 cells or PdpnKo cells transfected wild type Pdpn (WT), phosphomimetic Pdpn
(DD), or empty parental vector (EF4) was measured by video microscopy for 36 h (bar  20 m). b, migration of individual motile cells was quantitated as
micrometers traveled over 36 h (mean  S.E., n  5–10). c, the percentage of morphologically intact cells was used to quantitate the survival of cocultured
melanoma cells in a 600  600-m field (mean  S.E., n  4). Double and triple asterisks indicate p  0.01 and p  0.001 when compared with B16 cells cultured
with B16 cells by Student’s t test, respectively.
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cells transfected with PDPN (36, 37), melanoma tumorigenesis
(18), and glioma progression (38, 39) in mice.
A variety of signaling agents and cytokines can induce PDPN
expression and cell motility (5, 6, 40). For example, the Src
tyrosine kinase utilizes the Cas/BCAR1 adaptor protein to aug-
ment PDPN expression to promote transformed cell motility
required formalignant cells to break out of theirmicroenviron-
ment to become invasive and metastatic (4, 41).
Elucidating how PDPN promotes cell motility is necessary to
understand its role in tumorigenesis and its potential as a che-
motherapeutictarget.OurfindingsthatPDPNcanbephosphor-
ylated to inhibit cell migration and that PDPN expression influ-
ences the effects of fibroblasts on neighboring tumor cells shed
considerable light on this process. For example, modulators of
kinases or phosphatases may be employed to enhance the
effects of reagents targeting PDPN to treat a variety of cancers
(8–10), and possibly other diseases including psoriasis (40).
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